Skip to main content

Table 5 Genotyping pfmdr1 N86Y and pfk13 SNPs at D0, D1 and day of recurrent parasitaemia

From: Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether–lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tanzania: a randomized controlled trial

 Baseline control patientsaRecurrent infections
D0D0D1Day of parasite recurrence
pfmdr1 PCR success rate n/N,  %45/46, 97.835/35, 10034/35, 97.228/35, 80
pfmdr1 N86 prevalence, n/N, % (95% CI)43/45, 95.6 (84.9–99.5)b34/35, 97.1 (85–100)33/34, 97.1 (84.7–100)28/28, 100 (87.7–100)
pfk13 PCR success rate n/N, %42/46, 91.334/35, 97.130/35, 85.726/35, 74
Prevalence of SNPs in K13 n/N, % (95% CI)2/35, 5.9 (0.7–19.7)2/34, 5.9 (0.7–19.7)ND1/26, 3.9 (0.1–19.6)
  1. aBaseline control were D0 samples from 46 randomly selected patients (23 from each arm) without recurrent parasitaemia
  2. bThere was one patient out of 43 with mixed N/Y pfmdr1 genotype